CKD is increasing worldwide at an annual growth rate of 8%. Kidney impairment usually progresses through several well-defined stages. Diabetes & hypertension are most common contributors towards progression of kidney disease. The role of RAAS blockers has become very important in the management of kidney disease. These slides primarily focus on telmisartan & enumerates the data with this molecule in the treatment of CKD eg ESPRIT, TRENDY, DETAIL, AMADEO, etc.